Efficacy of Tixagevimab/Cilgavimab Prophylaxis and Vaccination on Omicron Variants (BA.1, BA.2, BA.5, and BQ.1.1) in Kidney Transplant Recipients
Clin J Am Soc Nephrol
.
2023 Oct 1;18(10):1343-1345.
doi: 10.2215/CJN.0000000000000241.
Epub 2023 Jun 29.
Authors
Dominique Bertrand
1
,
Charlotte Laurent
1
,
Veronique Lemée
2
,
Ludivine Lebourg
1
,
Mélanie Hanoy
1
,
Frank Le Roy
1
,
Dorian Nezam
1
,
Diana Pruteanu
1
,
Steven Grange
1
,
Tristan de Nattes
1
3
,
Mathilde Lemoine
1
,
Sophie Candon
3
4
,
Dominique Guerrot
1
5
Affiliations
1
Department of Nephrology, Transplantation and Hemodialysis, Rouen University Hospital, Rouen, France.
2
Department of Virology, Rouen University Hospital, Rouen, France.
3
INSERM U1234, University of Rouen Normandy, Rouen, France.
4
Department of Immunology and Biotherapies, Rouen University Hospital, Rouen, France.
5
INSERM U1096, University of Rouen Normandy, Rouen, France.
PMID:
37382950
PMCID:
PMC10578625
(available on
2024-10-01
)
DOI:
10.2215/CJN.0000000000000241
No abstract available
Publication types
Research Support, Non-U.S. Gov't
MeSH terms
Antibodies, Monoclonal
Humans
Kidney Transplantation* / adverse effects
Transplant Recipients
Vaccination
Substances
tixagevimab
cilgavimab
Antibodies, Monoclonal